A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Depressive Disorder Clinical Trial

Official title:

A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03315793
• Other study ID #: 14937
• Secondary ID: F1J-JE-B0581701A
• Status: Completed
• Phase: Phase 3
• Start date: December 4, 2017
• Est. completion date: November 8, 2019

Study information

• Verified date: December 1, 2020
• Source: Shionogi Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 149
• Est. completion date: November 8, 2019
• Est. primary completion date: November 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Years to 17 Years

Eligibility

Inclusion Criteria:

• Participants diagnosed with Major Depressive Disorder or persistent depressive disorder and completely meet the criteria of major depressive episode as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) ver.7.0.2.
• Participants whose incipient age of depression was =7 years old.
• Total score of CDRS-R is =40 and CGI-S score is =4 at both screening and baseline.

Exclusion Criteria:

• Have remarkable response to psycho-education (defined as >30% decrease in the total score of CDRS-R between screening and baseline).
• Have a current or previous diagnosis (DSM-5) of the following as judged by the

investigator:

• Neurodevelopmental disorders
• Schizophrenia spectrum and other psychotic disorders
• Bipolar and related disorders
• Trauma and stressor-related disorders
• Disruptive · Impulse Control · and Conduct disorders
• Have a current diagnosis (DSM-5) of the following as judged by the investigator:
• Obsessive-compulsive and related disorders
• Anorexia nervosa, Bulimia nervosa, Binge-eating disorder
• Sleep-wake disorders
• Neurocognitive disorders
• Disruptive mood dysregulation disorder
• Have personality disorders, in the judgement of the investigator.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Drug:
• Duloxetine Hydrochloride
Administered orally
• Placebo
Administered orally

Locations

Country	Name	City	State
Japan	Shionogi	Osaka

Sponsors (2)

Lead Sponsor	Collaborator
Shionogi	Eli Lilly and Company

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline on the Children's Depression Rating Scale-Revised (CDRS-R) Total Score	Change from baseline on the Children's Depression Rating Scale-Revised (CDRS-R) total score. CDRS-R Total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning and a higher number indicates a greater degree of depression. The total sum of scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, scores of 40 to 60 indicate moderate depression, and scores greater than 60 indicate severe depression. Least squares (LS) mean was calculated using a mixed-effects model repeated measures (MMRM) approach including treatment group, observation time-points, and interaction between treatment group and observation time-points as fixed effects, and baseline CDRS-R total score and age as covariates.	Baseline, Week 6
Secondary	Percentage of Participants Whose Children's Depression Rating Scale-Revised (CDRS-R) Total Score Decreased by More Than 30% From Baseline	The Children's Depression Rating Scale-Revised (CDRS-R) Total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning and higher numbers indicate a greater degree of depression. The total sum of scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, scores of 40 to 60 indicate moderate depression, and scores greater than 60 indicate severe depression.	Baseline, Week 6
Secondary	Percentage of Participants Whose CDRS-R Total Score Decreased by More Than 50% From Baseline	The Children's Depression Rating Scale-Revised (CDRS-R) total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning with higher numbers indicating a greater degree of depression . The total sum of scores range from 17 to 113. The total sum of scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, scores of 40 to 60 indicate moderate depression, and scores greater than 60 indicate severe depression.	Baseline, Week 6
Secondary	Percentage of Participants With Total Children's Depression Rating Scale-Revised (CDRS-R) Score = 28	The Children's Depression Rating Scale-Revised (CDRS-R) total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning and higher numbers indicate a greater degree of depression. The total sum of scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, scores of 40 to 60 indicate moderate depression, and scores greater than 60 indicate severe depression. Remission was defined for the CDRS-R total score below 28.	Baseline, Week 6
Secondary	Change From Baseline on Clinical Global Impression-Severity (CGI-S)	CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Presented here are the LS mean change from baseline on CGI-S calculated using a mixed-effects model repeated measures (MMRM) approach including treatment group, observation time-points, and interaction between treatment group and observation time-points as fixed effects, and baseline CGI-S and age as covariates.	Baseline, Week 6